天眼查App显示，近日，东莞卓智化妆品有限公司成立，注册资本10万人民币，经营范围为一般项目： 化妆品零售；化妆品批发；日用品销售；日用品批发；服装服饰零售；服装服饰批发；日用百货销售； 办公用品销售；服装辅料销售；美发饰品销售；珠宝首饰批发；皮革制品销售；家用电器销售；消毒剂 销售（不含危险化学品）；个人卫生用品销售；日用化学产品销售；针纺织品及原料销售；体育用品及 器材零售；体育用品及器材批发；卫生用品和一次性使用医疗用品销售；工艺美术品及收藏品零售（象 牙及其制品除外）；箱包销售；钟表销售；销售代理；互联网销售（除销售需要许可的商品）；品牌管 理；市场营销策划；企业形象策划；咨询策划服务；会议及展览服务；信息技术咨询服务；国内货物运 输代理；项目策划与公关服务；技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广。 （除依法须经批准的项目外，凭营业执照依法自主开展经营活动）。 ...

天眼查App显示，近日，碧臻化妆品（东莞）有限公司成立，法定代表人为叶伟伦，注册资本100万人 民币，经营范围为一般项目：化妆品批发；化妆品零售；专业设计服务；平面设计；传统香料制品经 营；工艺美术品及礼仪用品销售（象牙及其制品除外）；工艺美术品及收藏品零售（象牙及其制品除 外）；纸制品销售；塑料制品销售；橡胶制品销售；五金产品零售；包装材料及制品销售；家用电器销 售；日用品批发；玻璃仪器销售；金属包装容器及材料销售；箱包销售；销售代理；厨具卫具及日用杂 品批发；互联网销售（除销售需要许可的商品）；技术服务、技术开发、技术咨询、技术交流、技术转 让、技术推广；生产线管理服务；货物进出口；技术进出口；进出口代理。（除依法须经批准的项目 外，凭营业执照依法自主开展经营活动）。 ...

Core Viewpoint - The stock of Giant Bio (02367) experienced a significant increase of over 12% due to a share buyback announcement, but subsequently fell by over 4% [1] Group 1: Share Buyback Announcement - Giant Bio announced plans to exercise its share buyback authorization, allowing the company to repurchase up to 103.6 million shares, which represents 10% of the issued shares excluding treasury shares [1] Group 2: Sales Performance - According to a report from Bank of America Securities, sales for the Co-Beauty brand during the Double Eleven shopping festival were under pressure, with sales on Tmall and Douyin declining by 20% and 50% year-on-year, respectively [1] - In contrast, the Co-Li Jin brand achieved positive growth during the same period [1] Group 3: Earnings Guidance - Management has revised down the earnings guidance for the year, expecting revenue to remain flat or slightly decline year-on-year, and has lowered the net profit forecast to a year-on-year decline in the mid to high single digits [1]

Core Insights - The global expansion of South Korean cosmetics has reached a new level, with exports hitting record highs and diversifying into various segments, particularly in emerging markets like North America [1][3] - The shift from a "Korean Wave single product-driven" model to a systematic collaboration of technology, branding, channels, and culture has allowed Korean cosmetics to establish a sustained trend in international markets [1] Group 1: Export Performance - In the first three quarters of 2025, South Korea's cosmetics exports reached $8.52 billion (approximately 606.27 billion RMB), marking a year-on-year increase of 15.4% and setting a record for the same period [1] - The third quarter alone saw exports of $3 billion (approximately 213.48 billion RMB), a 17.6% increase year-on-year, achieving the highest quarterly export figure in history [1] - Korean cosmetics were exported to a record 205 countries and regions, with the U.S. being the largest market at $1.68 billion (approximately 119.46 billion RMB), accounting for 19.7% of total exports [3] Group 2: Product Structure and Innovation - The export structure shows that base makeup accounts for 41.7% of total exports, with a value of $3.55 billion (approximately 252.44 billion RMB), followed by sunscreen and anti-wrinkle products at 25.5% [6] - New Korean beauty brands like TIRTIR and Beauty of Joseon have gained popularity globally, with major retailers like Ulta Beauty and Sephora introducing these brands to their shelves [6] - The innovation in product forms, such as cushion foundations and "no-makeup" looks, has allowed Korean cosmetics to define new usage scenarios and experience standards [7][9] Group 3: Strategic Insights for Chinese Cosmetics - The successful strategy of Korean cosmetics involves shifting from a "shelf product" mentality to a "anchor product" approach, focusing resources on a few core categories to redefine industry standards [21] - Chinese cosmetics brands are encouraged to leverage their understanding of local skin types and aesthetics to create 1-2 "anchor products" that represent "Chinese creation" on a global scale [24] - The competition in global markets is evolving from ingredient-based competition to product definition, necessitating a focus on creating iconic product forms that address global pain points [27] Group 4: Cultural and Aesthetic Framework - The deeper support for Korean cosmetics globalization lies in a complete "Korean aesthetic system," which promotes values like youthfulness and natural beauty through cultural narratives [27] - Different brands contribute to the narrative of "K-Beauty," creating a rich and attractive image of Korean cosmetics as a cultural symbol [27] - For Chinese cosmetics, there is a need to develop a unique "Chinese aesthetic system" that resonates globally, drawing from deep cultural roots while translating them into contemporary design language [30]

Core Viewpoint - Shanghai Linqingxuan Cosmetics Group Co., Ltd. is advancing its IPO process on the Hong Kong Stock Exchange, aiming to become the "first high-end domestic skincare stock" in Hong Kong, with significant revenue and profit growth reported in the first half of the year [3][4]. Company Overview - Founded in 2003, Linqingxuan focuses on high-end domestic skincare products, particularly anti-wrinkle and firming products, with its flagship product being the Camellia Oil [5]. - The Camellia Oil has sold over 45 million bottles since its launch in 2014 and has consistently ranked first in retail sales among facial oils in China for 11 consecutive years [5][8]. Financial Performance - In the first half of this year, Linqingxuan's revenue surged by 98.3% to 1.052 billion yuan compared to the same period in 2024 [3]. - The adjusted net profit for the same period increased by 117.4% to 200 million yuan, nearly matching the total profit for the entire year of 2024 [4]. Product Development - Linqingxuan has developed a range of proprietary ingredients and products centered around Camellia, including various patented components that target specific skincare needs [7]. - As of June 30, 2025, the company offers 230 SKUs, including serums, creams, toners, and sunscreens, catering to diverse customer skincare needs [8]. Market Position - Linqingxuan ranks first among domestic high-end skincare brands in China and is the only domestic brand among the top 15 high-end skincare brands, including international brands [8]. - In the anti-wrinkle and firming segment, Linqingxuan is also the leading domestic brand and ranks among the top 10 overall [8]. Customer Engagement - The company has over 5.6 million active customers, with an average annual repurchase rate of approximately 33.5%, exceeding the industry average [9]. Distribution Channels - As of June 30, 2025, Linqingxuan operates 554 stores, primarily located in shopping malls, ranking first among domestic and international high-end skincare brands in terms of store count [11]. - The company has a strong online presence, with a compound annual growth rate of 51.2% in online revenue from 2022 to 2024, and a remarkable 137.2% year-on-year growth in the first half of this year [12]. Future Plans - Linqingxuan plans to initiate a global expansion strategy, starting with the Southeast Asian market [13]. - The funds raised from the IPO will be used for brand development, sales network enhancement, production capacity improvement, and digital infrastructure upgrades [14].

Core Insights - DR PLANT, known as Plant Doctor, has officially initiated its IPO process to list on the Shenzhen Stock Exchange, marking a significant step towards entering the A-share market [1] - The brand has established a strong market and brand foundation, leveraging its unique research capabilities and brand strategy to lead the trend of Eastern skincare and promote high-quality development of Chinese ingredients in the beauty industry [3] Research and Development - Since its inception, Plant Doctor has prioritized research and innovation as the core driver of its brand development, forming a strategic partnership with the Kunming Institute of Botany, Chinese Academy of Sciences in 2014 to establish the "Kunming Institute of Botany Plant Doctor R&D Center" [3][5] - The company has built a comprehensive R&D industrial chain consisting of "1 center and 5 bases," including various research facilities in Kunming, Beijing, Tokyo, and partnerships with Jiangnan University, focusing on the R&D and innovation of Chinese cosmetic ingredients [5] Market Position and Consumer Engagement - Plant Doctor has effectively captured consumer demand by focusing on "safety, effectiveness, and high quality" in product development, expanding its influence through a multi-channel approach [7] - As of June 2025, the brand has established 4,269 offline chain stores and ranked second in the beauty and body care sector of the CCFA's "Top 100 Chain Enterprises in Life Services" for 2022-2023, while being the top single-brand cosmetics store in China based on projected 2024 retail sales [7] Future Prospects - The IPO attempt on the Shenzhen Stock Exchange represents both a milestone and a new starting point for Plant Doctor, with potential to leverage capital to enhance its R&D system and expand both domestic and international markets [9] - Successful entry into the A-share market could allow the brand to further promote Chinese ingredients and Eastern skincare concepts on the international beauty stage, contributing to the high-quality development of the Chinese cosmetics industry [9]

Core Viewpoint - Shanghai Linqingxuan Cosmetics Group Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, focusing on high-end domestic skincare products, particularly anti-wrinkle and firming skincare solutions [1][2]. Company Overview - Linqingxuan is recognized for its high-end skincare brand in China, emphasizing natural camellia oil-based products and the "oil-based skincare" concept since 2012 [1]. - The company launched its first camellia oil facial essence in 2014, which has since sold over 45 million bottles, maintaining the top position in retail sales among all facial oil products in China for 11 consecutive years [1][2]. Financial Performance - Revenue figures for Linqingxuan from 2022 to 2025 (up to June 30) are as follows: RMB 6.85 billion, RMB 7.97 billion, RMB 11.98 billion, and RMB 10.42 billion, respectively, with the brand accounting for over 99% of total revenue during these periods [2][5]. - Gross profit for the same periods is reported as approximately RMB 5.39 billion, RMB 6.54 billion, RMB 9.98 billion, and RMB 8.66 billion [6]. Market Position - In 2024, Linqingxuan ranked first among all high-end domestic skincare brands in China, holding a 1.4% market share, and is the only domestic brand in the top 15 high-end skincare brands overall [2]. - The high-end skincare market in China is projected to grow from RMB 749 billion in 2019 to RMB 1,144 billion by 2024, with expectations to reach RMB 2,185 billion by 2029 [2]. Product Offering - Linqingxuan offers a comprehensive range of high-end skincare solutions, including essence oils, creams, toners, emulsions, serums, masks, and sunscreens, designed to support a complete skincare routine [1]. Sales Strategy - The company has established a comprehensive sales network utilizing an OMO (Online-Merge-Offline) approach, combining diverse online channels with a strong offline presence [4].

Core Viewpoint - Lin Qingxuan is accelerating its IPO process after receiving the CSRC filing notice, with updated IPO application materials now available on the Hong Kong Stock Exchange website [1] Company Overview - Lin Qingxuan, a pioneer in the "oil-based skincare" sector, has focused on anti-wrinkle and firming skincare products, becoming a leading brand in cell-level anti-wrinkle essence oils [1] - The company's flagship product, the Camellia Oil Anti-Wrinkle Repair Essence Oil, has ranked first in retail sales among all facial essence oil products in China for 11 consecutive years since 2014 [1] Financial Performance - The company's total revenue has shown consistent growth over the past three years, with a compound annual growth rate (CAGR) of 32.3%, increasing from RMB 691 million in 2022 to RMB 1.21 billion in 2024 [1] - In the first half of this year, the company achieved a net profit of RMB 182 million, with a gross margin of 82.4%, and the gross margin for the essence oil category reached 86.2% [1] Product Sales Performance - The Lin Qingxuan Black Gold Time Peptide Anti-Wrinkle Brightening Cream is projected to generate RMB 61.5 million in revenue for 2024, with RMB 50 million already achieved in the first half of 2025, making it one of the best-selling products [2] - The Lin Qingxuan High SPF Sunscreen has rapidly developed since its launch in 2024, generating RMB 36.3 million in its first year and increasing to RMB 42.1 million in the first half of this year, indicating strong market recognition [2] Industry Growth Potential - The market for high-end anti-wrinkle and firming skincare products is expected to grow from RMB 59.4 billion in 2024 to RMB 155.5 billion by 2029, with a CAGR of 21.2% [2] - The overall high-end skincare market in China is projected to reach RMB 218.5 billion by 2029, with a CAGR of 13.8% from 2024 to 2029 [2] - As a leading brand in the high-end domestic skincare industry, Lin Qingxuan is well-positioned to benefit from strong R&D capabilities and existing leading products [2]

Core Viewpoint - CICC has downgraded the net profit forecast for Giant Bio (02367) for 2025-2026 by 25% and 33% to 1.91 billion and 2.14 billion yuan respectively, citing short-term pressure on cosmetics sales. The current stock price corresponds to a P/E ratio of 20x for 2025 and 18x for 2026. The target price has been reduced by 20% to 56 HKD, which implies a potential upside of 41% based on the adjusted earnings forecast [1]. Company Current Situation - On December 2, the company announced a plan to repurchase up to 104 million shares, accounting for 10% of the issued shares, and is communicating its strategic plans for 2026 regarding product matrix expansion, brand operation, and channel development. This repurchase reflects management's confidence, and the company’s R&D capabilities, brand recognition, and team cohesion remain strong, suggesting potential operational improvements through optimized product structure and timely operational adjustments [2][3]. Product and Channel Expansion Plans - The company has a rich reserve of new products for 2026, with plans to launch four key new products in the collagen repair series and expand channel coverage for existing brands. The company aims to strengthen its online presence and expand offline channels, including clinics and self-operated stores, with successful initial steps in Southeast Asia. The contribution from second-tier products is expected to increase, driving healthy growth in the cosmetics business [4]. Medical Aesthetics Growth - The medical aesthetics team is expanding, with strong experience in developing star products and commercial preparations progressing smoothly. The company’s R&D strength, brand recognition, and team cohesion are expected to support long-term growth, especially as the cosmetics market recovers and the medical aesthetics segment contributes additional growth [5].

Core Viewpoint - CICC has downgraded the profit forecast for Giant Bio (02367) for 2025-2026 by 25% and 33% to 1.91 billion and 2.14 billion yuan respectively, reflecting short-term pressure on cosmetics sales. The current stock price corresponds to a P/E of 20x for 2025 and 18x for 2026. The target price has been reduced by 20% to 56 HKD, indicating a potential upside of 41% based on the adjusted profit forecast [1]. Company Current Situation - On December 2, the company announced a plan to repurchase up to 104 million shares, accounting for 10% of the issued shares, and communicated its strategic plans for 2026 regarding product matrix expansion, brand operation, and channel development. This repurchase reflects management's confidence, and the company is expected to improve operations through optimized product structure and timely operational adjustments [2][3]. Share Repurchase Plan - The company plans to use its own funds to repurchase up to 104 million shares, which may be canceled or held as treasury stock. This repurchase plan is seen as a demonstration of management's long-term confidence in the company's growth and is expected to enhance earnings per share and shareholder returns [3]. Product Matrix and Channel Expansion Planning - For 2026, the company has a rich reserve of new products, including four key new products from the core collagen stick marketing and pricing strategy. Additionally, the company plans to upgrade its product lines and expand channel coverage, including online influencer marketing and offline distribution channels. The second-tier products are expected to contribute to healthy growth in the cosmetics business [4]. Medical Aesthetics Second Curve Progress - The company's medical aesthetics team is expanding, with successful commercialization preparations based on previous experience in developing star products. The company maintains strong R&D capabilities, brand recognition, and team cohesion, suggesting a broad growth space as the cosmetics market recovers and the medical aesthetics segment contributes additional revenue [5].